IMUX vs NVS
IMUX: Immunic is a late-stage biotechnology firm developing oral, small-molecule treatments for multiple sclerosis and other neurodegenerative diseases, led by its flagship candidate, vidofludimus calcium. NVS: Novartis is a leading global pharmaceutical company focused on discovering and developing innovative, high-efficacy medicines across oncology, immunology, and neuroscience.
Side-by-side fundamentals
| Metric | IMUX | NVS | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $7.41 | $153.64 | |
| Market cap | $101M | $286.6B | |
| ROE FY2025, SEC XBRL | n/a | +30.0% | |
| ROA FY2025, SEC XBRL | -404.0% | +12.6% | NVS higher |
| Dividend yield as of 2026-09-03 | n/a | +3.4% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-02 | 1.07 | 0.22 | |
| 1-year return as of 2026-10-20 close | -11.4% | +16.6% | NVS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.